HKD 0.5
(-1.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 216.62 Million HKD | -18.04% |
2022 | 325.08 Million HKD | -19.58% |
2021 | 404.23 Million HKD | 8.21% |
2020 | 373.56 Million HKD | -18.58% |
2019 | 458.83 Million HKD | 12.76% |
2018 | 406.92 Million HKD | 10.24% |
2017 | 369.11 Million HKD | 22.42% |
2016 | 301.51 Million HKD | 17.69% |
2015 | 256.18 Million HKD | 44.39% |
2014 | 177.43 Million HKD | 0.45% |
2013 | 176.63 Million HKD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 120.24 Million HKD | -12.09% |
2023 Q2 | 129.63 Million HKD | -21.75% |
2023 FY | 266.42 Million HKD | -18.04% |
2023 Q4 | 136.78 Million HKD | 5.51% |
2022 FY | 325.08 Million HKD | -19.58% |
2022 Q4 | 165.68 Million HKD | 3.94% |
2022 Q2 | 159.4 Million HKD | -29.81% |
2021 Q2 | 177.14 Million HKD | -10.54% |
2021 FY | 404.23 Million HKD | 8.21% |
2021 Q4 | 227.09 Million HKD | 28.2% |
2020 Q2 | 175.56 Million HKD | -25.48% |
2020 FY | 373.56 Million HKD | -18.58% |
2020 Q4 | 198 Million HKD | 12.79% |
2019 FY | 458.83 Million HKD | 12.76% |
2019 Q2 | 223.25 Million HKD | 13.23% |
2019 Q4 | 235.58 Million HKD | 5.52% |
2018 FY | 406.92 Million HKD | 10.24% |
2018 Q4 | 197.16 Million HKD | -6.0% |
2018 Q2 | 209.75 Million HKD | 0.45% |
2017 Q2 | 160.3 Million HKD | -8.11% |
2017 Q4 | 208.8 Million HKD | 30.26% |
2017 FY | 369.11 Million HKD | 22.42% |
2016 FY | 301.51 Million HKD | 17.69% |
2016 Q2 | 127.05 Million HKD | -7.67% |
2016 Q4 | 174.45 Million HKD | 37.3% |
2015 Q2 | 118.57 Million HKD | 27.12% |
2015 FY | 256.18 Million HKD | 44.39% |
2015 Q4 | 137.61 Million HKD | 16.06% |
2014 Q4 | 93.27 Million HKD | 10.84% |
2014 FY | 177.43 Million HKD | 0.45% |
2014 Q2 | 84.15 Million HKD | 90.9% |
2013 FY | 176.63 Million HKD | 0.0% |
2013 Q4 | 44.08 Million HKD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Pak Fah Yeow International Limited | 24.42 Million HKD | -786.951% |
Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 94.389% |
Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -509.759% |
Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | 38.794% |
Qianhai Health Holdings Limited | 17.1 Million HKD | -1166.688% |
Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | 63.345% |
Essex Bio-Technology Limited | 1.22 Billion HKD | 82.373% |
Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | 56.972% |
SSY Group Limited | 1.98 Billion HKD | 89.063% |
JBM (Healthcare) Limited | 163.87 Million HKD | -32.191% |
Jacobson Pharma Corporation Limited | 287.34 Million HKD | 24.611% |
China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 99.262% |